Leukotriene synthesis and receptor blockers block hypoxic pulmonary vasoconstriction.

Pancreatitis-induced acute lung injury. An ARDS model. Ann Surg (1988) 1.21

Augmentation of hypoxic pulmonary vasoconstriction in the isolated perfused rat lung by in vitro antagonists of endothelium-dependent relaxation. J Clin Invest (1988) 1.12

Activation of C5 by cobra venom factor is required in neutrophil-mediated lung injury in the rat. Am J Pathol (1987) 1.06

Non-narcotic analgesics. Use in pregnancy and fetal and perinatal effects. Drugs (1986) 0.75

Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci U S A (1979) 5.33

Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest (2000) 5.26

Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med (2001) 3.92

Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol (1994) 3.83

Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J (2001) 3.20

Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J (2005) 2.82

Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol (2000) 2.73

The Function of Ac-Globulin in Blood Clotting. Science (1947) 2.62

Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest (1998) 2.54

Plasma and lipids from stored packed red blood cells cause acute lung injury in an animal model. J Clin Invest (1998) 2.37

The physicochemical characteristics and purification of slow-reacting substance of anaphylaxis. J Immunol (1973) 2.34

Structure of leukotriene C. Identification of the amino acid part. Biochem Biophys Res Commun (1979) 2.30

Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest (1995) 2.30

Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest (1997) 2.29

Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol (2001) 2.24

End points in pulmonary arterial hypertension: the way forward. Eur Respir J (2004) 2.21

Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med (1999) 2.21

Inactivation of slow reacting substance of anaphylaxins (SRS-A) by arylsulfatases. J Immunol (1974) 2.19

Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis. Aliment Pharmacol Ther (2014) 2.18

Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis. Circ Res (2001) 2.00

Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest (1987) 1.96

Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation (1982) 1.92

Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor gamma ligands and agonists. J Biol Chem (2001) 1.86

Inhibition of hypoxic pulmonary vasoconstriction by calcium antagonists in isolated rat lungs. Circ Res (1976) 1.76

Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res (2001) 1.75

Hypoxaemia and aortic chemoreceptor function in foetal lambs. J Physiol (1969) 1.68

Congenital pulmonary lymphangiectasis. Am J Dis Child (1970) 1.64

Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol (1999) 1.63

Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis (1990) 1.62

Hypoxia inducible factor-1α in human emphysema lung tissue. Eur Respir J (2010) 1.62

Proactive integrated care improves quality of life in patients with COPD. Eur Respir J (2009) 1.61

Operation Everest II: oxygen transport during exercise at extreme simulated altitude. J Appl Physiol (1985) (1988) 1.60

Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest (1999) 1.59

Nonimmunological production of leukotrienes induced by platelet-activating factor. Science (1982) 1.58

Operation Everest II: elevated high-altitude pulmonary resistance unresponsive to oxygen. J Appl Physiol (1985) (1987) 1.56

Immediate drainage is not required for all patients with complicated parapneumonic effusions. Chest (1990) 1.56

Cyanide stimulation of the systemic arterial chemoreceptors in foetal lambs. J Physiol (1969) 1.55

In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol (1998) 1.54

Hypothyroidism and primary pulmonary hypertension: an autoimmune pathogenetic link? Ann Intern Med (1993) 1.51

Crystal structure of the SarR protein from Staphylococcus aureus. Proc Natl Acad Sci U S A (2001) 1.48

Smooth muscle-mediated connective tissue remodeling in pulmonary hypertension. Science (1987) 1.47

Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol (1997) 1.46

Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J Appl Physiol (1985) (2001) 1.44

High-frequency ventilation. Chest (1989) 1.44

High-altitude pulmonary edema in the children and young adults of Leadville, Colorado. N Engl J Med (1977) 1.43

Internal carotid arterial flow velocity during exercise in Tibetan and Han residents of Lhasa (3,658 m). J Appl Physiol (1985) (1992) 1.43

Trehalose-containing lipooligosaccharides. A new class of species-specific antigens from Mycobacterium. J Biol Chem (1983) 1.41

Histamine H1- and H2-receptors in pulmonary and systemic vasculature of the dog. Am J Physiol (1975) 1.40

Severe pulmonary hypertension and arterial adventitial changes in newborn calves at 4,300 m. J Appl Physiol (1985) (1987) 1.40

Activation of the epidermal platelet-activating factor receptor results in cytokine and cyclooxygenase-2 biosynthesis. J Immunol (1998) 1.39

Remodeling of arachidonate-containing phosphoglycerides within the human neutrophil. J Biol Chem (1986) 1.37

The genetic factor influencing pulmonary hypertension in cattle at high altitude. Cardiovasc Res (1974) 1.30

HOX genes in human lung: altered expression in primary pulmonary hypertension and emphysema. Am J Pathol (2001) 1.29

Leukotriene generation by eosinophils. J Exp Med (1982) 1.29

Chronic obstructive bronchopulmonary disease. II. Oxygen transport in two clinical types. Am J Med (1968) 1.28

The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med (2001) 1.27

Transcellular metabolism of neutrophil-derived leukotriene A4 by human platelets. A potential cellular source of leukotriene C4. J Biol Chem (1988) 1.25

Electrospray mass spectrometric analysis of 5-hydroperoxy and 5-hydroxyeicosatetraenoic acids generated by lipid peroxidation of red blood cell ghost phospholipids. J Am Soc Mass Spectrom (1998) 1.25

Pulmonary hypertension and inflammation. J Lab Clin Med (1998) 1.25

Inflammatory platelet-activating factor-like phospholipids in oxidized low density lipoproteins are fragmented alkyl phosphatidylcholines. J Biol Chem (1999) 1.25

Operation Everest II: pulmonary gas exchange during a simulated ascent of Mt. Everest. J Appl Physiol (1985) (1987) 1.24

The pressure-overloaded right ventricle in pulmonary hypertension. Chest (1998) 1.24

Pancreatitis-induced acute lung injury. An ARDS model. Ann Surg (1988) 1.21

The case for treatment of selected patients with primary pulmonary hypertension. Am Rev Respir Dis (1986) 1.21

Cytochrome P-450 metabolism of arachidonic acid: formation and biological actions of "epoxygenase"-derived eicosanoids. Pharmacol Rev (1988) 1.21

Novel glutathione conjugates formed from epoxyeicosatrienoic acids (EETs). Arch Biochem Biophys (1985) 1.21

Isocratic separation of some purine nucleotide, nucleoside, and base metabolites from biological extracts by high-performance liquid chromatography. J Chromatogr (1976) 1.20

Leukotrienes and slow reacting substance of anaphylaxis (SRS-A). Allergy (1980) 1.19

5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. Am J Respir Crit Care Med (1998) 1.18

Pre-excitation as a cause of appearance and increased intensity of systolic murmurs. Circulation (1966) 1.17

Introduction of a nomenclature: leukotrienes. Prostaglandins (1979) 1.16

Expression of the platelet-activating factor receptor results in enhanced ultraviolet B radiation-induced apoptosis in a human epidermal cell line. J Biol Chem (1998) 1.16

Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. Am J Respir Crit Care Med (2001) 1.16

Isoproterenol as a potential pulmonary vasodilator in primary pulmonary hypertension. Am J Cardiol (1978) 1.15

Failure of hypoxic pulmonary vasoconstriction in patients with liver cirrhosis. J Clin Invest (1972) 1.15

Identification of functional platelet-activating factor receptors on human keratinocytes. J Invest Dermatol (1995) 1.15

Leukotrienes: a new group of biologically active compounds. Adv Prostaglandin Thromboxane Res (1980) 1.15

Analysis of epoxyeicosatrienoic and monohydroxyeicosatetraenoic acids esterified to phospholipids in human red blood cells by electrospray tandem mass spectrometry. J Mass Spectrom (1997) 1.14

Acclimatization to 4,300-m altitude decreases reliance on fat as a substrate. J Appl Physiol (1985) (1996) 1.14

Factors modifying the early nondiuretic vascular effects of furosemide in man. The possible role of renal prostaglandins. Circ Res (1983) 1.14

Phosphatidylethanolamine has an essential role in Saccharomyces cerevisiae that is independent of its ability to form hexagonal phase structures. J Biol Chem (2001) 1.13

Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP. Am J Respir Cell Mol Biol (1997) 1.13

Fast atom bombardment tandem mass spectrometric identification of diacyl, alkylacyl, and alk-1-enylacyl molecular species of glycerophosphoethanolamine in human polymorphonuclear leukocytes. Anal Chem (1992) 1.13

Leukotriene C4 and D4 in neonates with hypoxemia and pulmonary hypertension. N Engl J Med (1983) 1.11

Bioactive phospholipid oxidation products. Free Radic Biol Med (2000) 1.11

Hypoxic ventilatory responsiveness in Tibetan compared with Han residents of 3,658 m. J Appl Physiol (1985) (1993) 1.11

12(R)-hydroxyicosatetraenoic acid: a cytochrome-P450-dependent arachidonate metabolite that inhibits Na+,K+-ATPase in the cornea. Proc Natl Acad Sci U S A (1987) 1.11

PAF antagonists inhibit pulmonary vascular remodeling induced by hypobaric hypoxia in rats. J Appl Physiol (1985) (1992) 1.10

Inhibition of leukotriene biosynthesis in mastocytoma cells by diethylcarbamazine. Biochem Pharmacol (1982) 1.10

Lung vascular smooth muscle as a determinant of pulmonary hypertension at high altitude. Am J Physiol (1975) 1.09

Increased dependence on blood glucose after acclimatization to 4,300 m. J Appl Physiol (1985) (1991) 1.09

Measurement of peptidoleukotrienes in biological fluids. J Appl Physiol (1985) (1990) 1.08

Systemic hypertension at 4,300 m is related to sympathoadrenal activity. J Appl Physiol (1985) (1994) 1.08

Measurement of cardiac output by electrical impedance at rest and during exercise. J Appl Physiol (1976) 1.08

Muscle accounts for glucose disposal but not blood lactate appearance during exercise after acclimatization to 4,300 m. J Appl Physiol (1985) (1992) 1.08